EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOMES OF PERIPHERAL T-CELL LYMPHOMA IN LATIN AMERICA

Autor: Fischer, T, Idrobo, H, Pavlovsky, A, Castro, D, Beltran, B, Enriquez, DJ, Vasquez, JF, Roche, C, Artiles, D, Valvert, F, Villela, LM, Pereira, J, Oliver, C, Tavares, JV, Brasil, SAB, Cecyn, KZ, Castro, N, Baptista, RLR, Medina, SS, Borducchi, DMM, Bellesso, M, Farias, DLC, Gonzaga, YB, Warley, F, Fiad, L, Korin, L, Pereyra, PH, Pena, C, Torres, MA, Mahuad, CV, Glasenapp, AV, Quiroz, AR, Gazitua, R, Samane-Figari, CA, Sardu, L, Arriola, JP, Isnardi, S, Maradei, JL, Gabus, RH, Enrico, AI, Guanchiale, LA, Arangueren, FN, Altuve, JIG, Cerutti, A, Penalva, R, Trucco, JIG, Pessolani, F, Gilli, V, Diaz, J, Martinez, ME, Jarchum, G, Perinotto, GC, Barraza, T, Ciarlo, S, Rojas, C, Jiménez, ROR, Souza, CA, Miranda, ECM, Federico, M, Valcarcel, B, Chiattone, CS, Castillo, LEM

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2023 45 Supplement 4:S367-S368

Blood and bone marrow transplantation for acute myeloid leukemia.

Autor: Villela LM, Bolaños-Meade J

Publikováno v: Clinical Leukemia; Aug2009, Vol. 3 Issue 2, pE11-21, 1p

HIV-1 controllers exhibit an enhanced antiretroviral innate state characterised by overexpression of p21 and MCPIP1 and silencing of ERVK-6 RNA expression.

Autor: de Azevedo SSD; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de AIDS & Imunologia Molecular, Rio de Janeiro, RJ, Brasil., Ribeiro-Alves M; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laboratório de Pesquisa Clínica em DST/AIDS, Rio de Janeiro, RJ, Brasil., Côrtes FH; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de AIDS & Imunologia Molecular, Rio de Janeiro, RJ, Brasil., Delatorre E; Universidade Federal do Espírito Santo, Centro de Ciências da Saúde, Departamento de Patologia, Laboratório de Genômica e Ecologia Viral, Vitória, ES, Brasil., Hoagland B; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laboratório de Pesquisa Clínica em DST/AIDS, Rio de Janeiro, RJ, Brasil., Villela LM; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laboratório de Pesquisa Clínica em DST/AIDS, Rio de Janeiro, RJ, Brasil., Grinsztejn B; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laboratório de Pesquisa Clínica em DST/AIDS, Rio de Janeiro, RJ, Brasil., Veloso VG; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laboratório de Pesquisa Clínica em DST/AIDS, Rio de Janeiro, RJ, Brasil., Morgado MG; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de AIDS & Imunologia Molecular, Rio de Janeiro, RJ, Brasil., Souza TML; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Imunofarmacologia, Rio de Janeiro, RJ, Brasil.; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças de Populações Negligenciadas, Rio de Janeiro, RJ, Brasil., Bello G; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de AIDS & Imunologia Molecular, Rio de Janeiro, RJ, Brasil.; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Arbovírus e Vírus Hemorrágicos, Rio de Janeiro, RJ, Brasil.

Publikováno v: Memorias do Instituto Oswaldo Cruz [Mem Inst Oswaldo Cruz] 2024 Sep 16; Vol. 119, pp. e240071. Date of Electronic Publication: 2024 Sep 16 (Print Publication: 2024).

Ongoing HIV-1 evolution and reservoir reseeding in two elite controllers with genetically diverse peripheral proviral quasispecies.

Autor: de Azevedo SSD; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de AIDS & Imunologia Molecular, Rio de Janeiro, RJ, Brasil., Côrtes FH; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de AIDS & Imunologia Molecular, Rio de Janeiro, RJ, Brasil., Villela LM; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, RJ, Brasil., Hoagland B; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, RJ, Brasil., Grinsztejn B; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, RJ, Brasil., Veloso VG; Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, RJ, Brasil., Morgado MG; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de AIDS & Imunologia Molecular, Rio de Janeiro, RJ, Brasil., Bello G; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de AIDS & Imunologia Molecular, Rio de Janeiro, RJ, Brasil.

Publikováno v: Memorias do Instituto Oswaldo Cruz [Mem Inst Oswaldo Cruz] 2023 Jun 05; Vol. 118, pp. e230066. Date of Electronic Publication: 2023 Jun 05 (Print Publication: 2023).

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.

Autor: Takuva S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa., Karuna ST; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Juraska M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Rudnicki E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Edupuganti S; Division of Infectious Disease, Department of Medicine, Emory University, Atlanta, GA., Anderson M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., De La Grecca R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Gaudinski MR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Sehurutshi A; Botswana Harvard AIDS Institute, Gaborone, Botswana, South Africa., Orrell C; Department of Medicine, Desmond Tutu HIV Center, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Naidoo L; South African Medical Research Council, Durban, South Africa., Valencia J; Asociacion Civil Impacta Salud y Educacion, Lima, Peru., Villela LM; Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil., Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA., Andrew P; Family Health International, Durham, NC., Karg C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Randhawa A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Hural J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Gomez Lorenzo MM; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Burns DN; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Ledgerwood J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Cohen M; Department of Medicine, University of North Carolina, Chapel Hill, NC., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Mngadi K; Aurum Institute, Johannesburg, South Africa; and., Mgodi NM; University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.

Publikováno v: Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2022 Apr 01; Vol. 89 (4), pp. 405-413.